Navigation Links
Agendia Supports High Profile CME Symposium and Presents Compelling Data at the 2008 San Antonio Breast Cancer Symposium
Date:12/8/2008

HUNTINGTON BEACH, California and AMSTERDAM, December 8 /PRNewswire/ -- Agendia, a world leader in molecular cancer diagnostics, today announced that leading Agendia and the Netherlands Cancer Institute researchers will present data from multiple studies at the 2008 San Antonio Breast Cancer Symposium (SABCS) and Agendia will support, with an unrestricted grant, the New Frontiers in Individualized Breast Cancer Therapy symposium. The San Antonio Breast Cancer Symposium, one of the premiere conferences in breast cancer research worldwide, takes place December 10th-14th, 2008.

The New Frontiers in Individualized Breast Cancer Therapy symposium, an important continuing medical education event at the SABCS, will take place on Saturday, December 13, from 7:30-10 pm, at the Grand Hyatt, San Antonio. Additionally, a mini-symposium and a series of poster presentations will highlight results from studies analyzing Agendia's MammaPrint(R), a FDA-cleared test that identifies the risk of breast cancer recurrence and provides doctors with the rationale to assess the benefits of chemotherapy.

Full study results will be discussed at a mini-symposium and the following embargoed poster sessions and discussions:

    Thursday, 12/11/08, 5:30pm - 7:30pm
    #1063, Poster Session 1: Prognostic Factors and Biomarkers -
    Clinical Testing and Validation, "The 70-gene prognosis profile predicts
    early metastases in postmenopausal breast cancer patients." Presenter:
    Stella Mook, MD, Netherlands Cancer Institute.

    Thursday, 12/11/08, 5:30pm - 7:30pm CST
    #1084, Poster Session 1: Prognostic Factors and Biomarkers -
    Clinical Testing and Validation, "Benefit of the 70-gene profile for
    widely used guidelines: an answer to increased selection for adjuvant
    chemotherapy in breast cancer." Presenter: Michael Knauer, M.D.,
    Netherlands Cancer Institute.

    Friday, 12/12/08, 2pm - 3:30pm CST
    Mini-symposium 2, Molecular Profiling for Guiding Therapeutic
    Decisions: "RNA".
    Presenter: Laura Van 't Veer, PhD, Netherlands Cancer Institute.

    Friday, 12/12/08, 5pm - 7pm CST
    #305 Poster Discussion 3: Circulating Tumor Cells and Marrow
    Micrometastases, "A multi-marker QPCR panel for the detection of
    circulating tumor cells predicts survival in breast cancer patients."
    Presenter: Laura Van 't Veer, PhD, Netherlands Cancer Institute.

    Friday, 12/12/08, 5pm - 7pm CST
    #3007, Poster Session 3: Detection/Diagnosis - Diagnostic
    Pathology, "Microarray-based determination of ER, PR and HER2 receptor
    status: validation and comparison with IHC assessments." Presenter: Paul
    Roepman, PhD, Agendia.

    Saturday, 12/13/08, 7am - 9am CST
    #4171, Poster Session 4: Late Acceptances, "Identification of
    a low risk subgroup in Her2-positive breast cancer by the 70-gene
    prognosis signature." Presenter: Michael Knauer, MD, Netherlands Cancer
    Institute

    Sunday, 12/14/08, 7am - 9am
    #6034, Poster Session 6: Prognosis and Response Predictions -
    Biomarkers and Other Factors, "Biology of Breast Cancers that Are Screen
    Detected vs. Locally Advanced or Young Age Should Inform How We Approach
    Early Detection and Prevention." Presenter: Laura Esserman, MD, UCSF
    Carol Franc Buck Breast Care Center.

New Frontiers in Individualized Breast Cancer Therapy

The New Frontiers in Individualized Breast Cancer Therapy symposium updates physicians on the latest information regarding the development of molecular diagnostic assays for breast cancer and how to integrate this information into their everyday practices. The technology behind multigene expression profiling assays will be discussed, including immunohistochemistry, RT-PCR, and DNA microarray-based assays. The use of microarray technology in breast cancer sub-typing will also be covered as well as key clinical data from prospective validation studies establishing these assays as prognostic and/or predictive in patients with node-negative early-stage breast cancer. Comparisons of molecular profiling assays to traditional clinicopathologic criteria and online algorithms will be reviewed, and the utility of these assays in patients with node-positive disease and ongoing clinical trials of multigene assays in breast cancer will be discussed. For more information please go to NewFrontiers.CancerLearning.com.

The faculty will consist of:

William F. Symmans, MD, Assistant Professor of Pathology, The University of Texas M. D. Anderson Cancer Center, Houston, TX

Kelly K. Hunt, MD, F.A.C.S, Professor of Surgery, Department of Surgical Oncology, Chief Surgical Breast Section, The University of Texas M. D. Anderson Cancer Center, Houston, TX; Chair Breast Committee, American College of Surgeons Oncology Group

Rowan T. Chlebowski, MD, PhD, Professor of Medicine, UCLA School of Medicine, Chief of Medical Oncology at Harbor-UCLA Medical Center, Torrance, CA.

Emiel J Rutgers, MD, PhD, Professor of Surgery, Department of Surgical Oncology, Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands

About MammaPrint(R)

MammaPrint is the first 'in vitro diagnostic multivariate index assay' (IVDMIA) cleared by the U.S. Food and Drug Administration (FDA). FDA clearance requires clinical and analytical validation and reporting systems to ensure patient safety issues are addressed. Highly accurate, MammaPrint identifies patients with early metastasis - those patients who are likely to develop metastases within five years following surgery. Several authoritative studies have shown that chemotherapy particularly reduces early metastasis risk. In planning treatment, the MammaPrint test result provides a doctor with a clear rationale to assess the benefit of adjuvant chemotherapy in addition to other clinical information and pathology tests.

All MammaPrint tests are conducted in Agendia's CLIA-certified service laboratory. All other breast cancer recurrence assays currently marketed have not been subject to the rigorous FDA clearance process.

About Agendia

Agendia is at the forefront of the personalized medicine revolution, striving to bring more effective, individualized treatments within reach of patients. Building on a cutting edge genomics platform for tumor gene expression profiling, the company's tests aim to help physicians more accurately tailor cancer treatments. The company markets four products with several new genomic tests under development. In addition, Agendia collaborates with pharmaceutical companies to develop highly effective personalized drugs in the area of oncology. Agendia is based in Huntington Beach, California, and in Amsterdam, The Netherlands. For more information please visit http://www.agendia.com.


'/>"/>
SOURCE Agendia BV
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Agendias MammaPrint(R) Included in 2008 Dutch Institute for Healthcare Improvement CBO Guidelines
2. Agendia Launches TargetPrint(R) for Breast Cancer Patients
3. APTA Supports Surgeon Generals Call to Action to Prevent Deep Vein Thrombosis and Pulmonary Embolism
4. Analysis of Earlier European Stroke Trial Supports Treatment Regimen for Viprinex(TM) in Current International Phase 3 Clinical Trials
5. DSMB Again Supports Continuation of Alimera Sciences Phase 3 Clinical Trial of Iluvien(TM) for the Treatment of DME
6. New Data Presented at WCTRIMS* Supports the Importance of Early and Sustained Treatment with Betaseron(R)
7. NicOx Announces Second Naproxcinod Pivotal Phase 3 Study (302) Meets Efficacy Primary Endpoints and Supports Non-Detrimental Blood Pressure Effect
8. Journal of Antimicrobial Chemotherapy Paper Supports Additional Role for Cethromycin as Potential Treatment for Infections Caused by Community- Associated Methicillin Resistant Staphylococcus Aureus (CA-MRSA)
9. Study Supports Possible Use of Leukine(R) as a Potential Adjuvant Therapy for High-Risk Melanoma Patients
10. Data To Be Presented at ASCO Supports Potential of Peregrines Cotara(R) for the Treatment of Brain Cancer
11. International Diabetes Federation Grant Supports Lifestyle Intervention Study to Prevent Type 2 Diabetes in India
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... 24, 2016  Global Blood Therapeutics, Inc. (GBT) (NASDAQ: ... novel therapeutics for the treatment of grievous blood-based ... closing of its previously announced underwritten public offering ... public offering price of $18.75 per share. All ... by GBT. GBT estimates net proceeds from the ...
(Date:6/24/2016)... , June 24, 2016 ... has announced the addition of the " Global ... This report ... provides an updated review, including its applications in various ... total market, which includes three main industries: pharmaceutical and ...
(Date:6/24/2016)... 2016 The Academy of Managed Care Pharmacy ... that would allow biopharmaceutical companies to more easily share ... formulary and coverage decisions, a move that addresses the ... The recommendations address restrictions in the sharing ... drug label, a prohibition that hinders decision makers from ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... ... issues and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the ... several important health care topics including advance care planning, healthcare costs and patient ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe ... from the David Geffen School of Medicine at UCLA. He trained in Internal Medicine ... his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the ...
(Date:6/24/2016)... ... ... Those who have experienced traumatic events may suffer from a complex set of ... or alcohol abuse, as a coping mechanism. To avoid this pain and suffering, Serenity ... event. , Trauma sufferers tend to feel a range of emotions, from depression, guilt, ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience with ... Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Haute Beauty Network, ... M. Weintraub as a prominent plastic surgeon and the network’s newest partner. ... the most handsome men, look naturally attractive. Plastic surgery should be invisible.” He ...
Breaking Medicine News(10 mins):